BAFF (BLys) and APRIL: Emerging Targets for autoimmune disease & Cancer Therapeutics

Questions: Discounts, Updates etc.

Price (Single): £450

Price (Departmental): £750

Price (Company): £950

Publication Date: 2006-01-01

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

In 1999 Human Genome Sciences researchers published a study in the journal Science describing a new member of the TNF super-family which they named BLyS.  Since that time our understanding of this protein, also known as BAFF, and its homologue APRIL has progressed rapidly.  The BAFF sub-family has emerged as a candidate target for therapies of various autoimmune diseases and hematological cancers with breathtaking speed. 

In April 2005, LymphoStat-B, HGS' neutralizing anti-BAFF monoclonal antibody, met the primary efficacy and safety endpoints in a Phase 2 clinical trial in patients with rheumatoid arthritis.  A few months later a Phase 2 study also demonstrated efficacy in systemic lupus erythematosus. Earlier this month Zymogenetics announced Phase 1 data on TACI-Ig, a decoy receptor designed to block APRIL and BAFF.  This molecule is also showing promising activity in hematological cancers.

The continuing success of Rituxan has established a proof of concept for the development of B-cell targeted therapeutics as treatments of a broad range of autoimmune disorders and hematological cancers and global annual sales are now well in excess of $2 billion.  Therapeutics targeting the BAFF sub-family stand to offer significant competition to Rituxan yet advanced development is currently restricted to LymphoStat-B and TACI-Ig.  LeadDiscovery’s analysts believe that this drug class is far from optimized, offering companies with an interest in autoimmune disease or cancer significant opportunities. 

Our brand new drug discovery report BAFF & APRIL: Emerging Targets for autoimmune & Cancer Therapeutics offers a detailed look at BAFF and APRIL focusing on:

In short, if your company is looking to enter the emerging field of BAFF this report will provide all the key information necessary to help you fast track this process.

Some of our key conclusions are:

  • There is particularly good evidence to support a role of BAFF in the etiology of rheumatoid arthritis although based on cross-study comparison the efficacy of the lead therapeutic in this class, LymphoStat-B, appears to be inferior to Rituxan. LymphoStat-B blocks just BAFF however APRIL is also elevated in the synovial fluid of rheumatoid arthritis patients.  We conclude that dual blockade of APRIL as well as BAFF may be required for optimal therapeutic activity.  Data from ZymoGenetic’ study of TACI-Ig may shed some light on this issue. 
  • Immunosuppressive adverse effects of BAFF/APRIL blockers should be less than those resulting from Rituxan
  • Blocking BAFF and/or APRIL may be a useful adjuvant to TNF blockers, increasing efficacy while possibly reducing the heightened risk of lymphoma associated with this major therapeutic class.
  • There is good evidence to suggest that BAFF contributes to the etiology of systemic lupus erythematosus however optimal selectivity of therapeutic agents aimed at BAFF remains to be established. 
  • Of all the autoimmune conditions investigated, the serum levels of BAFF are highest in Sjögren's syndrome.  One particularly attractive advantage of blocking BAFF and/or APRIL is that this approach may prevent the development of lymphomas, a co-morbidity associated with a subgroup of patients. 
  • Other autoimmune diseases that have yet to fall under the spotlight of BAFF/APRIL should be evaluated as target indications. In particular multiple sclerosis and inflammatory bowel disease may represent potential indications.
  • Strong evidence supports the blockade of BAFF/APRIL as a treatment of multiple myeloma and non-Hodgkin’s lymphoma.  Elevated levels of these molecules may limit the efficacy of existing therapeutic agents, while their blockade is likely to act in an additive or possible synergistic fashion with steroids or IL-6 therapeutics.

Table of Contents

An introduction to B-cell immunology

Regulation of B-cell function by TNF family members

Autoimmune disease

A pathophysiological role for BAFF and APRIL in hematological cancers

Blocking BAFF/APRIL

Market potential and competition

Summary & Strategic Recommendations

Other users found this report page using the following search terms: baff blyss autoimmune baff blys april arthritis rheumatoid autoimmune baffblys blyss disease blysbaff

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.